TrueNorth Wealth & Impact, LLC’s AstraZeneca AZN Stock Holding History

TrueNorth Wealth & Impact, LLC’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$437K	Buy	+2,711	New	+$452K	0.17%	96

Other funds holding AZN

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $162B AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

TrueNorth Wealth & Impact, LLC's AZN Position: Q3 2026 in Review

TrueNorth Wealth & Impact, LLC opened a new position in AstraZeneca (AZN) in Q3 2026: 2,711 shares worth $437K. The stake represents 0.17% of the portfolio and ranks #96 among its holdings.

1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

TrueNorth Wealth & Impact, LLC held 2,711 shares of AstraZeneca worth $437K as of Q3 2026.
AstraZeneca was a new TrueNorth Wealth & Impact, LLC position in Q3 2026.
AstraZeneca made up 0.17% of TrueNorth Wealth & Impact, LLC's portfolio in Q3 2026, its #96 holding.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on TrueNorth Wealth & Impact, LLC's 13F filing for Q3 2026, filed 13 Nov 2026.